Avivagen Announces New E.U. Broiler Poultry Trial

(via Thenewswire.ca)

Ottawa, ON / TheNewswire / January 27, 2016 / - Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a life sciences company commercializing products intended to eliminate the need for preventative or growth promoting antibiotics in livestock feeds and otherwise support human and animal health, announces the start of a new broiler poultry trial with the Institute of Agro-food Research & Technology of Catalonia, Spain (IRTA).

This trial will test the efficacy of OxC-beta(TM) Livestock to enhance performance and welfare of healthy broiler chickens raised under typical production conditions. Subject to minor enhancements to the protocol, the trial is a replicate of the study conducted by IRTA for Avivagen in 2015.

During that former trial, birds were subjected to a prolonged and unintended heat-stress due to a record heat wave in Spain that overwhelmed the facility's cooling system. Avivagen and IRTA have agreed that the heat-stress was likely to have impacted the trial outcomes. Avivagen provided summary information about that trial protocol and its results in a news release dated October 22, 2015. Results of that trial suggested the higher dose of OxC-beta had protective effects for birds facing the experimental stress challenges.

It is expected that the in-vivo portion of the current trial will be completed in 35 days, to be followed by related ex-vivo analyses. Avivagen will make further disclosures relating to the results of this trial following its receipt and review of data from IRTA concerning the various components of the trial.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV" and on OTC Pink as "CHEXF." The Company's goal is to develop and deliver scientifically-proven products that benefit human and animal health. Its target markets include livestock health and productivity, companion animal quality-of-life and maintaining optimal health in humans.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About Avivagen's Technology

Avivagen has a proprietary and patented technology from its discoveries about carotenoid oxidation. The food-borne oxidation compounds discovered by Avivagen help the body's own systems to maintain and enhance health, by supporting immune function against bacteria and calming excess inflammation. Avivagen's commercial-stage application of its inventions is fully-oxidized beta-carotene, OxC-beta(TM) Technology (OxC-beta). OxC-beta occurs naturally as carotenoid oxidation products in vegetation, but in minute amounts. Avivagen is developing OxC-beta as a replacement for the use of antibiotics for growth promotion and disease prevention in livestock feeds, to enhance the quality of life of companion animals and to help maintain optimal health in humans. Avivagen's commercial products are OxC-beta(TM) Livestock (Kingdom of Thailand), Vivamune(TM) Vital Health3 Chews (U.S.) and Oximunol(TM) Chewable Tablets (U.S.).

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, referenced trials or their outcomes, the expected timelines for trial completion or related disclosures, corporate goals or management's opinions, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive; even if the results of trials are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained; the timing and results of trials may be delayed or may not be completed at all; and intellectual property rights may prove inadequate to protect its inventions. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.

Cameron Groome, CEO & President
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright (c) 2016 TheNewswire - All rights reserved.